# NEOLA (NCT06194448)

> To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06194448
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Lung Cancer
- Interventions: Osimertinib; Cisplatin or Carboplatin; Pemetrexed or Paclitaxel; Radiation
- Enrollment: 76
- Primary outcome: PFS (Progression-Free Survival)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5
- Podcasts: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=neola-nct06194448

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06194448", "email": "<work email>"}; the inbox owner confirms by the emailed link.